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istorically, psychiatric disorders such as mood
disorders and schizophrenia have been conceptualized
as neurochemical illnesses. However, accumulating data
from both postmortem and brain imaging studies reveal
morphological changes in the brains of individuals with
these illnesses. These changes include ventricle enlarge-
ment, volumetric reduction, attenuation of neuronal via-
bility marker N-acetyl aspartate (NAA), and atrophy or
loss of neurons and glial cells in selective cortical and
limbic brain regions. Several psychotropic agents—
defined as chemical substances that act primarily on the
central nervous system (CNS) to alter brain function—
are used to treat psychiatric disorders. These psy-
chotropic agents include mood stabilizers, antidepres-
sants, and antipsychotic medications. Many of these
drugs exert significant effects on signaling pathways
enhancing neurotrophic and neuroprotective cellular
mechanisms. Loosely defined, neurotrophic effects can be
considered a therapeutic strategy intended to augment
proliferation, differentiation, growth, and regeneration,
whereas neuroprotective effects slow or halt the progres-
sion of neuronal atrophy or cell death following the
onset of disease or clinical decline. 
In this article, we review evidence from animal and human
studies reporting that psychotropic agents affect molecu-
lar targets and signaling cascades associated with enhanced
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Accumulating evidence suggests that psychotropic agents
such as mood stabilizers, antidepressants, and antipsy-
chotics realize their neurotrophic/neuroprotective effects
by activating the mitogen activated protein kinase/extra-
cellular signal-related kinase, PI3-kinase, and
wingless/glycogen synthase kinase (GSK) 3 signaling path-
ways. These agents also upregulate the expression of
trophic/protective molecules such as brain-derived neu-
rotrophic factor, nerve growth factor, B-cell lymphoma 2,
serine-threonine kinase, and Bcl-2 associated athanogene
1, and inactivate proapoptotic molecules such as GSK-3.
They also promote neurogenesis and are protective in
models of neurodegenerative diseases and ischemia. Most,
if not all, of this evidence was collected from animal stud-
ies that used clinically relevant treatment regimens.
Furthermore, human imaging studies have found that
these agents increase the volume and density of brain tis-
sue, as well as levels of N-acetyl aspartate and glutamate
in selected brain regions. Taken together, these data sug-
gest that the neurotrophic/neuroprotective effects of
these agents have broad therapeutic potential in the
treatment, not only of mood disorders and schizophrenia,
but also neurodegenerative diseases and ischemia. 
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reverse or reduce behavioral deficits associated with pre-
clinical animal models of mania and depression and other
psychiatric illnesses. While much of this work has focused
on the mood stabilizers lithium and valproate, we will also
review the available evidence that antidepressants and
antipsychotics exert similar neurotrophic effects.
Mood stabilizers
Mood stabilizers are used to treat bipolar disorder (BPD),
which is characterized by mood shifts between mania
(characterized by elevated mood, increased energy,
impaired judgment, and racing thoughts) and depression
(characterized by low mood, anhedonia, etc). These ther-
apeutic agents do not simply target a particular neuro-
transmitter system or cellular signaling cascade, but diverse
targets implicated in many signaling pathways. This may
be because mood stabilizers were often designed to treat
different disorders, and their use in the treatment of BPD
frequently arose through serendipity; for instance, the
mood stabilizers carbamazepine and valproate—both used
to treat the manic symptoms of BPD—have anticonvul-
sant properties and were developed for the treatment of
epilepsy. In addition, our incomplete understanding of the
pathophysiology of BPD, in which both genetic and envi-
ronmental predispositions may impair cellular resilience
and lead to dysfunctional circuits and synapses, further
supports the notion that these agents affect diverse targets.
Indeed, mood stabilizers may achieve their therapeutic
effects by working through these diverse targets to restore
cellular resilience; notably, however, chronic treatment is
necessary for their neurotrophic and neuroprotective
actions to improve functional plasticity in cortical and lim-
bic circuits and synapses. 
Below we focus on several intracellular signaling path-
ways targeted by mood stabilizers that may underlie
these therapeutic mechanisms: i) the mitogen activated
protein kinase/extracellular signal-related kinase
(MAPK/ERK) pathway, ii) the phosphatidylinositol 3
kinase (PI3K) pathway, and ii) the wingless/glycogen
synthase kinase 3 (Wnt/GSK3) pathway. 
Mood stabilizers activate neurotrophic signaling 
pathways
Mood stabilizers have been reported to activate the intra-
cellular MAPK/ERK signaling pathway  (Figure 1).
1-3This
pathway is used by neurotrophins, neurotransmitters, and
neuropeptides to exert their neurotrophic and neuropro-
tective effects by specifically enhancing progenitor cell
proliferation and differentiation, neuronal process growth
and regeneration, neuronal survival, and long-term synap-
tic remodeling and plasticity.
4-7The key components of the
pathway are three serine/threonine-selective kinases:
RAF, MEK, and MAPK/ERK. GTP bond RAS, a small
G protein, induces RAF activity. RAF then phosphory-
lates and activates MEK, which in turn phosphorylates
and activates MAPK/ERK. The targets of ERK include
protein kinases such as RSK and MNK, ion channel, neu-
rotransmitter receptors, and transcription factors. RSK
and MNK are thought to phosphorylate and activate tran-
scription factor cAMP response element binding
(CREB). CREB regulates the expression of many differ-
ent genes, including B-cell lymphoma 2 (Bcl-2)
1,8 and
brain-derived neurotrophic factor (BDNF)
9 to enhance
neuroprotection and neuronal survival mechanisms.
In SH-SY5Y human neuroblastoma cells, the mood sta-
bilizers lithium and valproate activated AP-1 transcrip-
tion factors, and that activation was blocked by a MEK
inhibitor.
10That study also demonstrated that valproate
increased levels of activated phospho-ERK and reporter
gene expression driven by ELK, an ERK-regulated tran-
scription factor; that activation was further blocked by
RAS and RAF functional null mutant.
10 Valproate also
promoted neurite outgrowth and expression of GAP-43
in these cells, which could be blocked by an ERK path-
way inhibitor.
10 Taken together, these data indicate that
valproate activates the ERK pathway and produces neu-
rotrophic-like cellular effects through this activation.
Follow-up studies showed that in cultured cerebral cor-
tical cells, valproate induced ERK pathway activation in
a manner that was more sustainable than activation by
growth factors.
3
Valproate-induced activation of the ERK pathway has also
been identified in primary cortical neurons,
11 cerebral prog-
enitor cells,
12 hippocampal progenitor cells,
13 and endothe-
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BDNF brain-derived neurotrophic factor
CREB cAMP response element binding
ERK extracellular signal-related kinase
MAPK mitogen activated protein kinase
NAA N-acetyl aspartate
P13K PI3-kinase
Wnt/GSK wingless/glycogen synthase kinase
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14 Lithium similarly increased activation-phospho-
rylation of ERK in SY5Y cells,
15 cerebellar granular cells,
16,17
hippocampal progenitor cells,
18,19 and primary cortical neu-
rons.
11 Lithium inhibited the ERK pathway in cultures of
serum-deprived, quiescent astrocytes.
17 Furthermore, lam-
otrigine, an anticonvulsant prescribed to prevent recur-
rences of depression or mania in BPD, did not affect the
ERK pathway in SH-SY5Y cells
15 or primary cortical neu-
rons
11; however, lamotrigine still showed neuroprotective
effects in models of ischemia and kainate (KA)-induced
neurotoxicity, perhaps through glutamate release inhibi-
tion.
20,21Taken together, these in vitro data suggest that acti-
vation of the ERK pathway is common to only a subgroup
of mood stabilizers and is cell-type specific. 
In a series of in vivo studies, Chen and colleagues found
that chronic treatment with lithium or valproate
increased levels of activated phospho-ERK, phospho-
RSK1, and activated phospho-CREB in prefrontal cor-
tex and hippocampus.
2,3 Lithium-induced increases in
activated phospho-ERKs were also observed in the cau-
date/putamen of infant mouse brains.
22 Another study
found that valproate increased levels of activated phos-
pho-ERK and activated phospho-CREB in mice with
intracerebral hemorrhage.
23 Another study found that
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Figure 1. Intracellular signaling pathways targeted by psychotropic agents. The MAPK/ERK, PI3K, and Wnt/GSK3 signaling cascades. Psychotropic agents
such as mood stabilizers, antidepressants, and antipsychotics target these signaling cascades. Targets reported to be regulated by antidepres-
sants, antipsychotics, mood stabilizers (red), or multiple types of treatments (orange) are highlighted. Molecules in blue are critical constituents
of the selected pathways that have not been found to be affected by any of the treatments discussed in this review. Arrowheads indicate acti-
vation; circles indicate inhibition. Akt, serine/threonine protein kinase AKT; BAG-1, Bcl-2 associated athanogene; Bcl-2, B-cell lymphoma 2;
BDNF, brain-derived neurotrophic factor; CREB, cAMP response element binding; ERK, extracellular regulated kinase; GSK-3, glycogen syn-
thase kinase 3; HDAC, histone deacetylase; PI3K, phosphatidylinositol 3 kinase; TrkB, neurotrophic tyrosine kinase receptor, type 2; Ras, resis-
tance to audiogenic seizures; Raf, RAF proto-oncogene serine/threonine-protein kinase; RSK, ribosomal protein S6 kinase, 90kDa; MEK or
Map2k1, mitogen-activated protein kinase kinase 1; CBP; CREB binding protein; RNA POLII, RNA polymerase II; HAT, histone acetyltransferase;
PDK, pyruvate dehydrogenase kinase; APP-AB, amyloid beta (A4) precursor protein; Wnt, wingless
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els in the nucleus accumbens, and reduced phospho-
ERK levels in the amygdala,
24 suggesting that mood sta-
bilizer-induced ERK pathway activation/inactivation
may be brain region-specific.
The phosphatidylinositol 3 kinase (PI3K) pathway—a
regulator of neuronal survival and plasticity—is also reg-
ulated by growth factors (Figure 1).
6,25-27 Upon trophic
factor stimulation (Figure 1), the regulatory subunit of
PI3K is stimulated by the adapter proteins Grb-2 and
Grb-2-associated binding protein 1/2 (Gab1/2), resulting
in PI3K activation. The catalytic subunit of PI3K is also
stimulated by direct interaction with activated RAS.
Activated PI3K converts plasma membrane lipid phos-
phatidylinositol-4,5-biphosphate (PIP2) to phos-
phatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 pro-
vides docking sites for phosphoinositide-dependent
kinase (PDK) and the serine-threonine kinase Akt (also
known as protein kinase B, PKB). Simultaneous binding
of PDK and Akt at the PI3K activation site facilitates
phosphorylation of Akt by PDK1 and enhances Akt
activity. Akt then phosphorylates glycogen synthase
kinase-3 (GSK-3), which in contrast to most phospho-
rylations, leads to the inactivation of this enzyme.
28 PI3K,
PDK, Akt, and GSK-3 are thought to be the major com-
ponents of the PI3K pathway.
Mood stabilizers target several of these major components
of the PI3K pathway. Acute (minutes to hours) or suba-
cute (several days) lithium treatment of cerebellar gran-
ule cells, for instance, increased levels of activated phos-
pho-Akt as well as phospho-GSK-3, a product of
Akt-catalyzed phosphorylation.
29 Interestingly, similar
effects were noted in human SH-SY5Y cells treated with
lithium and valproate.
1,30The increases were blocked by
PI3K inhibitors, indicating that they required PI3K acti-
vation.
29 Chronic lithium and valproate treatment also
increased levels of phospho-GSK-3β in mouse cerebral
cortex and hippocampus.
30-32 Lithium injections (200 mg/kg
of body weight, IP) significantly increased levels of phos-
pho-Akt, phospho-GSK-3α and phospho-GSK-3β in the
striatum of dopamine transporter knockout (DAT KO)
mice within 30 minutes of administration.
33 Valproate
increased activated brain phospho-Akt in skeletal muscle
in a mouse model of Duchenne’s muscular dystrophy,
34 as
well as in a mouse model of intracerebral hemorrhage.
23
These data demonstrate that lithium and valproate stimu-
late the PI3K pathway in vivo and subsequently inactivate
GSK-3.
Mood stabilizers upregulate levels of neurotrophic and
neuroprotective molecules
Studies show that lithium and valproate increased
mRNA and protein levels of neurotrophins such as
BDNF, glial cell-line derived neurotrophic factor
(GDNF), neurotrophin 3 (NT-3), and vascular endothe-
lial growth factor (VEGF) in cultured cells and brain
regions.
2,35-46 Furthermore, lithium increased serum
BDNF levels in patients with Alzheimer’s disease.
47The
effects of mood stabilizers on BDNF levels are thought
to be mediated via several different mechanisms. These
mechanisms may include enhancing BDNF promoter
activation
40,43,45 by stimulating the ERK and PI3K path-
ways using lithium or valproate, leading to CREB acti-
vation and CRE-mediated gene transcription of BDNF.
Valproate’s inhibition of histone deacetylase (HDAC)
via an epigenetic mechanism—a molecular process that
leads to gene activation and deactivation—may also play
a role.
40,43,45
In addition to targeting neurotrophic mechanisms, mood
stabilizers also target neuroprotective molecules such as
Bcl-2. Bcl-2 and its family proteins are the major modu-
lators of apoptosis. Notably, numerous studies have
shown that chronic treatment with lithium or valproate
upregulates Bcl-2 and Bcl-2 associated athanogene
(BAG-1) levels in the brain or nerve tissues.
23,32,48-54This
upregulation appears to be partially due to activation of
the ERK and PI3K pathways, as well as increased tran-
scriptional activity of CREB.
1
Mood stabilizers promote neurogenesis and neuronal
process growth
The discovery that mood stabilizers can regulate growth
factors and produce neurotrophin-like molecular effects
led investigators to explore whether these agents could
augment hippocampal neurogenesis. Lithium and val-
proate were indeed found to promote hippocampal neu-
rogenesis in neuronal cell culture and rodent stud-
ies.
3,18,19,32,55 In vitro evidence showed that lithium induced
neuronal differentiation of hippocampal neural progen-
itor cells via a phospho-ERK and phospho-CREB
dependent pathway.
19 An in vivo study showed that
lithium increased survival of newborn cells in hip-
pocampus, and that an ERK pathway inhibitor blocked
lithium’s survival effects.
56Valproate activated the ERK
pathway and promoted differentiation of hippocampal
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neural progenitor cells in culture; however, valproate’s
differentiation effects were thought to be mediated
through HDAC inhibition, not ERK pathway activa-
tion.
13,57Whether valproate uses multiple mechanisms to
induce hippocampal neurogenesis in intact animals
remains to be elucidated.
Valproate also promoted neurite growth in cultured cells
(for reviews see refs 6,7), which was blocked by ERK
pathway inhibition.
3,10 Animal studies have found that
valproate facilitated axonal regeneration and motor func-
tion recovery after sciatic nerve axotomy.
51,58 Lithium sim-
ilarly enhanced survival and axonal regeneration of cul-
tured retinal ganglion cells,
4 protected retinal ganglion
cells following partial optic nerve crush in rats,
59 and pro-
moted axonal regeneration of rubrospinal tract (RST)
neurons following injury to the spinal cord.
53These neu-
roprotective findings are, in part, thought to be mediated
by Bcl-2. Another recent study showed that lithium facil-
itated motor function recovery and axonal regeneration
after spinal cord injury, and these effects were associated
with increased inactivated-phospho-GSK-3. Further sup-
port for GSK-3’s role in lithium’s neuroprotective effects
came from a study where lithium’s effects were mimic-
ked by the GSK-3 inhibitor SB415286.
60
Another area where lithium exerts neuroprotective
effects is in stress-induced morphological alterations.
Chronic behavioral stress shortens apical dendrites in
the CA3 region of the hippocampus in rodents. Lithium
treatment initiated 2 weeks before the stress and con-
tinued throughout a 3-week period of stress attenuated
these stress-induced reductions in apical dendritic
lengths.
61 Although the molecular mechanisms of this
lithium-induced morphological action are still not fully
understood, they are particularly important because
social-psychological and behavioral stress cause a vari-
ety of brain changes and are key contributing factors to
mood disorders.
62-65
Evidence from human imaging studies for 
neurotrophic/neuroprotective actions of mood 
stabilizers
As noted previously, brain imaging studies show brain
ventricular enlargements,
66,67 cortical regional morpho-
metric reductions,
68-72 and cerebral and hippocampal
level reductions of NAA
72-78 in individuals with mood dis-
orders, especially in unmedicated patients with a family
history of mood disorders. 
Intrigued by the discovery that Bcl-2 is upregulated by
mood stabilizers, investigators used imaging tools to
assess the effects of mood stabilizers on brain morpho-
metric and neurochemical measures. In a magnetic res-
onance imaging (MRI) study, Moore and colleagues
found that lithium treatment increased cerebral grey
matter volume.
79 Similar findings were also obtained in
other longitudinal and cross-sectional studies of cerebral
grey matter volume,
80 left anterior cingulate volume,
70
right anterior cingulate volume,
81 hippocampal volume,
82-86
and amygdala volume.
86 A cross-sectional study found
that valproate similarly increased left anterior cingulate
volume in individuals with BPD.
87
One initial longitudinal MRS study found brain regional
increases in NAA levels in individuals with BPD and
healthy subjects treated for 4 weeks with lithium,
79 a
finding replicated by other investigators.
88-90 NAA levels
were also found to be correlated with brain lithium lev-
els in a study of elderly patients with BPD.
91 Valproate
was similarly found to increase hippocampal NAA lev-
els.
72
Mood stabilizers produce neuroprotective effects in
animal models of disease 
Mood stabilizers are known to protect cultured cells
from a variety of insults (for reviews see refs 6,7,92,93).
In this section, we review the neuroprotective effects of
lithium and valproate in a series of models of brain
ischemia, neurodegeneration, and neuroinflammation
(eg, cerebral ischemia, Alzheimer’s disease (AD),
Huntington’s disease, amyotrophic lateral sclerosis
(ALS), HIV-associated cognitive impairments, and spin-
ocerebellar ataxia).
In a seminal study using an animal model of ischemia,
Chuang and colleagues found that ischemic infarct size
induced by occlusion of the left middle cerebral artery
was markedly reduced by lithium treatment adminis-
tered before
94 or after
95 the induction of ischemia; these
findings have since been replicated by other investiga-
tors.
96-104 Follow-up studies showed that valproate had
similar protective effects on ischemia-induced brain
infarction.
105,106
ALS is a progressive, lethal neurodegenerative disease
with no known cure. Riluzole, which prolongs the sur-
vival of patients by several months, is the only FDA-
approved treatment for this disease. Interestingly, rilu-
zole itself has been associated with neuroprotective
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107 SOD1-G93A mice, a model for ALS, carry
a high copy number of this transgene with the G93A
human SOD1 mutation. Studies show that valproate
108
and lithium
109,110 both delay disease onset and prolong
lifespan in SOD1-G93A mice. Furthermore, lithium and
valproate together produce an additive protective effect
in SOD1-G93A mice compared with either treatment
alone.
110 Notably, a clinical trial found that lithium, com-
pared with riluzole, further delays disease progression
and death in individuals with ALS.
109
With regards to AD, diverse studies have suggested that
lithium’s neuroprotective effects may have a potential
role in the therapeutics of this disease. AD is a leading
cause of dementia in the aging population and the most
common neurodegenerative disease without an effective
treatment. Briefly, the histological hallmarks of AD
include amyloid plaques, neurofibrillary tangles, and
neuronal loss. The plaques consist of insoluble deposits
of amyloid-beta (Aβ) protein and cellular material out-
side and around neurons. Aβ protein is derived from
amyloid precursor protein (APP) through an endopro-
teolytic cleavage catalyzed by β- and γ-secretase.
Mutations in the genes of presenilins—the core compo-
nent of γ-secretase, APP, and tau are associated with AD.
One series of experiments in cultured cells found that
GSK-3α increased Aβ production,
111 and that chronic
lithium treatment reduced Aβ produced in a genetic
mouse model of AD. These mice expressed APP-
Swedish (Tg2576) and also carried a knock-in mutation
of presenilin-1 (PS1P264L). In a transgenic mouse strain
overexpressing mutated (London V717I and Swedish
K670M/N671L) human APP (hAPP751), lithium treat-
ment reduced Aβ production, improved performance in
the water maze, and preserved dendritic structure in the
frontal cortex and hippocampus, all of which are associ-
ated with decreased APP phosphorylation and increased
levels of phospho-GSK-3β.
112 In another animal model
of AD where APP23 transgenic mice carried human
APP751 cDNA with the Swedish double mutation at
positions 670/671, Qing and colleagues observed that
valproate treatment decreased Aβ production, reduced
neuritic plaque formation, and improved memory
deficits; these effects were also associated with increased
phospho-GSK-3β.
113,114
Neurofibrillary tangles are formed by hyperphosphory-
lated tau, a microtubule-associated protein. GSK-3 is a
major tau kinase and GSK-3β hyperactivity is known to
contribute to tau hyperphosphorylation in cell and ani-
mal models. Interestingly, lithium treatment reduced tau
phosphorylation in the brains of mice overexpressing
mutated (London V717I and Swedish K670M/N671L)
human APP (hAPP751).
112 In another AD model
(3xTG-AD), lithium treatment reduced brain tau phos-
phorylation and increased brain GSK-3α and β phos-
phorylation at the inhibitory sites; however, it did not
improve memory or reduce Aβ protection.
115
Given these promising preclinical data, studies began to
examine the potential long-term neurotrophic/
neuroprotective effects of lithium and valproate in
humans. While some studies suggest that naturalistic
lithium treatment may indeed be associated with neu-
roprotective effects in individuals with AD (see, for
instance refs 47,116-118), considerably more data are
required. Nevertheless, this remains a promising and
exciting area for further investigation. 
Spinocerebellar ataxia type 1 (SCA1) is a dominantly
inherited neurodegenerative disorder characterized by
progressive motor and cognitive dysfunction. In a SCA1
mouse model, chronic administration of lithium initiated
before or after the deficit onset had a positive effect on
multiple behavioral measures and hippocampal neu-
ropathology.
119 Indeed, clinical trials of lithium in patients
with SCA1 are currently ongoing (see http://clinicaltri-
als.gov/ for more information).
Finally, the neuroprotective effects of lithium and val-
proate have also been reported in additional disease and
insult models, including animal models of Huntington’s
disease,
120,121 Parkinson's disease,
122 HIV-induced encephali-
tis and dementia,
123,124 and aluminum-induced neurode-
generation.
50At least some of these effects are associated
with increased Bcl-2 levels.
50,120,121,122
Antidepressants
Chemical antidepressants used to treat depressive dis-
orders, or depressive symptoms in other psychiatric dis-
orders, include monoamine oxidase inhibitors (MAOIs),
tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), or selective norepinephrine
reuptake inhibitors (SNRIs). These chemical antide-
pressants act by increasing monoamines (serotonin
and/or norepinephrine) in the synaptic cleft, which
occurs immediately; however, for most patients, thera-
peutic effects are observed only after a few days, and
often not until 2 weeks or more. This suggests that adap-
tive changes in cellular signaling cascades may underlie
Pharmacological aspects
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125 Two such pathways that will
be considered below include the MAPK/ERK and the
Wnt/GSK signaling cascade (Figure 1), which may
enhance neurotrophic and neuroprotective mechanisms
in addition to neurogenesis. Interestingly, nonchemical
antidepressants such as electroconvulsive therapy (ECT)
and exercise also target these pathways and may employ
similar therapeutic mechanisms. 
Antidepressants affect prominent signaling cascades
involved in neuronal protection and survival 
As noted above, activation of the MAPK/ERK and
Wnt/GSK signaling cascades (Figure 1) ultimately targeted
by antidepressants may result in enhanced neuroprotec-
tive and survival mechanisms. For instance, both chemical
antidepressants and ECT increase BDNF levels. In rats,
ECT increased BDNF and its receptor (trkB) in the hip-
pocampus.
126 A similar effect was also found following
chronic (21 days) but not acute treatment with different
classes of antidepressants (the MAOI tranylcypromine, the
SSRI sertraline, and the TCA desipramine). Furthermore,
chronic antidepressant treatment also increased the
expression of CREB mRNA in the rat hippocampus,
127
suggesting a potential regulatory mechanism for BDNF
through CRE-mediated gene transcription.
Exercise has also been reported to upregulate many fac-
tors in the MAPK signaling pathway including BDNF,
trkB, MEK2, and ERK2.
128-133A recent study found that
exercise-induced upregulation of BDNF at the mRNA
and protein level and phosphorylation of survival factor
Akt both occurred via a CREB-dependent mecha-
nism.
134 Interestingly, the SNRI reboxetine also depends
on CREB activation (phosphorylation) in order to show
similar changes in BDNF and Akt.
In humans, serum levels of BDNF levels are decreased
in unmedicated depressed patients compared with
depressed patients currently taking antidepressants or
healthy controls.
135 BDNF serum levels were also found
to be negatively correlated with depression scores as
assessed by the Hamilton Depression Rating Scale
(HDRS). Interestingly, BDNF itself also possesses anti-
depressant-like effects in rodent models used to screen
antidepressants following direct infusion into either the
midbrain
136 or hippocampus.
137 This enhancement in
BDNF by antidepressants may help promote mecha-
nisms of neuronal protection and survival key to reduc-
ing stress-induced damage.
Antidepressants have also been found to have neuro-
protective effects. For instance, the SSRI fluoxetine pre-
vented the neurotoxic effects of ecstasy (3,4-methylene-
dioxymethamphetamine, MDMA).
138,139 Mechanistically,
fluoxetine’s neuroprotective effects, in addition to restor-
ing serotonin levels, may result from activation of p38
MAPK, BDNF, and GDNF.
140
MAOIs (eg, pargyline, nialamide, tranylcypromine)
inhibiting both MAO-A and MAO-B protected against
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-
induced dopaminergic neural toxicity.
141 Interestingly,
Ladostigil, a MAOI used to treat both depression and
neurodegeneration that has promising neuroprotective
effects, reportedly activated Bcl-2 family members and
BDNF
142 in addition to ERK1/2 (p44/42 MAPK).
143
Notably, exercise also possesses neuroprotective effects.
Carro and colleagues showed that rodents subjected to
treadmill running were protected against various insults
ranging from treatment with the neurotoxin domoic acid
to inherited neurodegeneration affecting Purkinje cells
of the cerebellum.
144 These protective effects depended
in part on the neurotrophic factor insulin-like growth
factor I (IGF-1); infusing a blocking anti-IGF-1 antibody
reduced the protective effects of exercise.
Effects of antidepressants on neurogenesis in animals
Antidepressants increase hippocampal adult neurogen-
esis following chronic but not acute treatment. Chronic
treatment with the SSRI fluoxetine, the MAOI tranyl-
cypromine, or the SNRI reboxetine produced an
approximately 20% to 40% increase in bromodeoxyuri-
dine BrdU-labeled hippocampal cells
145; at least 2 weeks
of fluoxetine treatment was required to enhance neuro-
genesis. Furthermore, while stress decreases hippocam-
pal neurogenesis, chronic antidepressant treatment pre-
vented these stress-induced changes.
146,147 ECT also
increased neurogenesis in rodents,
148 as well as hip-
pocampal synapse number.
149 ECT was similarly found
to increase neurogenesis in nonhuman primates,
150 and
exercise increased hippocampal neurogenesis
151 in addi-
tion to enhancing hippocampal-dependent learning and
long-term potentiation (LTP).
151
The molecular mechanisms underlying these antide-
pressant-induced enhancements in neurogenesis may
involve the MAPK/ERK and/or Wnt/GSK-3 pathways.
A very recent study found that suppression of the gene
disrupted in schizophrenia 1 (DISC1), which has been
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and schizophrenia, decreased neurogenesis by acting
through GSK3β.
152
Antidepressants and the reversal of stress-induced
changes in neuronal plasticity
In terms of clinical implications, a recent meta-analysis
found enhanced antidepressant response in the Met
variant of the BDNF 66Val/Met polymorphism in indi-
viduals with MDD.
153 Curiously, 66Met allele carriers
have a lower neuronal distribution of BDNF in addition
to decreased activity-dependent BDNF secretion. Given
the hypothesis that antidepressant effects are partially
mediated through enhanced BDNF secretion, it would
seem contradictory that 66Met allele carriers, with their
attenuated BDNF secretion, have a more robust
response to antidepressants. In addition to enhanced
antidepressant treatment response, this BDNF poly-
morphism was also associated with decreased episodic
memory performance, lower hippocampal activation (as
measured by fMRI), and lower hippocampal NAA lev-
els in humans.
154 In a mouse model of the BDNF-Met
variant in which BDNF-Met was expressed at normal
levels, but regulated secretion from neurons was
reduced, fluoxetine was unable to ameliorate a stress-
induced anxiety phenotype.
155Taken together, these data
suggest a more complicated picture that requires a bet-
ter understanding of proper BDNF function (and not
just its expression); however, normal BDNF function
does appear to be important for proper hippocampal
function and mood regulation.
Notably, severely depressed patients show elevated lev-
els of the stress hormone cortisol, which is thought to
result from a dysfunctional hypothalamic-pituitary-
adrenal (HPA) axis negative feedback circuit,
156,157 and
which may ultimately contribute to the hippocampal
damage and volumetric changes reported in the litera-
ture. Subjects with MDD were found to have signifi-
cantly smaller hippocampal volumes, and these reduc-
tions correlated with total duration of depression but not
with age,
158,159 suggesting that the stress associated with
depression may have contributed to these volumetric
changes. Further support for this notion comes from
studies reporting that individuals with post-traumatic
stress disorder (PTSD) had impaired hippocampal func-
tion (deficits in short term memory, total recall, long-
term storage, and retrieval) but no overall IQ differences
when compared with controls
160; MRI studies found that
these PTSD patients had an 8% smaller right hip-
pocampus than controls.
161 In addition, the polymor-
phism in the BDNF gene (val(66)met) has also been
associated with reduced hippocampal volume.
162
Interestingly, antidepressants can reverse some of these
changes. In tree shrews, the selective serotonin reuptake
enhancer (SSRE) tianeptine prevented the decreased
brain metabolites (NAA, creatine, phosphocreatine),
suppressed neurogenesis, and reduced hippocampal vol-
ume associated with chronic psychosocial stress.
147 In
another study, chronic treatment with antidepressants
induced hippocampal neurogenesis, blocked inescapable
foot shock stress-induced decreases in hippocampal neu-
rogenesis, and normalized corticosterone levels and
behavioral deficits.
145,163 Finally, repetitive transcranial
magnetic stimulation (rTMS) has also shown putative
neurotrophic properties in patients with MDD. In one
study, rTMS improved refractory depression by aug-
menting catecholamines and BDNF,
164 while another
study found that rTMS augmented BDNF in drug-resis-
tant patients.
165
Antipsychotics
Antipsychotic medications are traditionally categorized
as typical (also known as traditional, conventional, or
classic neuroleptics) or atypical (second generation).
Several typical antipsychotics have a higher dopamine D2
receptor affinity than atypical antipsychotics, which bind
to a broader group of receptors, including dopamine,
serotonin, glutamate, histamine, α-adrenergic, and mus-
carinic receptors.
166 While antipsychotics can have an
immediate impact on symptoms such as agitation, it often
takes weeks before improvement is seen in other symp-
toms, such as delusions; however, recent findings suggest
these improvements may emerge more rapidly than pre-
viously believed.
167,168As with mood stabilizers and anti-
depressants, it is likely that these drugs improve many
facets of psychosis through mechanisms beyond their
fundamental interaction with dopaminergic, serotoner-
gic, muscarinic, and other receptor families.
Chronic treatment with conventional antipsychotics can
lead to adverse extrapyramidal side effects (EPS), which
mimic the neurodegenerative disorder Parkinson’s dis-
ease, as well as the potentially irreversible condition
known as tardive dyskinesia.
169 These effects are less
common with atypical antipsychotics, which also have
Pharmacological aspects
340
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 340improved efficacy in treating the negative symptoms
associated with schizophrenia, though their overall ben-
efit is still unclear
170; atypical antipsychotics also have
their own adverse metabolic side effects like weight gain
and diabetes.
171 As highlighted below, these two classes
of antipsychotics show markedly different profiles for
activating neuroplasticity cascades, and for enhancing
neuroprotection and neurogenesis in both animal stud-
ies and patient-based studies. 
Antipsychotics alter the expression of prominent 
intracellular cascades and influence neuroplasticity
and neuroprotection in animal models
Studies conducted in rodents and cell lines have demon-
strated that some antipsychotics can induce significant
changes in intracellular cascades that are involved in
neuroplasticity and neuroprotection against excitotoxic
insults, including ERK/MAPK, Akt, Bcl-2, and BDNF
pathways. Acute treatment with the atypical antipsy-
chotic clozapine led to increased levels of active (phos-
phorylated) MEK1/2 in rat prefrontal cortex,
172 while
chronic treatment with the atypical antipsychotic olan-
zapine increased pERK1/2 levels in rat prefrontal cor-
tex (PFC).
173 Interestingly, Browning and colleagues
observed decreases in pERK1/2 following either a sin-
gle injection of olanzapine or haloperidol (a typical
antipsychotic), but chronic haloperidol did not alter
pERK1/2 levels. Multiple studies in phenochromocy-
toma (PC12) cells have also noted upregulation of
pERK1/2, pAkt, and PI3K following olanzapine treat-
ment.
174,175Antipsychotics have also been shown to influ-
ence other prominent cascades discussed above, includ-
ing Bcl-2,
176 GSK-3,
177 and CREB.
178
Many studies have assessed the effects of antipsychotics
on neurotrophic factors such as BDNF and nerve
growth factor (NGF), and have noted significant differ-
ences between typical and atypical antipsychotics.
Typical antipsychotics such as haloperidol tend to reduce
BDNF expression in regions of the hippocampus
179-181
and striatum.
182 Atypical antipsychotics do not consis-
tently downregulate BDNF, and their more diverse set
of responses make critical evaluations more challenging
(see ref 183). One recent study noted that, after chronic
(90-day) treatment with haloperidol, transitioning to the
atypical antipsychotics olanzapine or risperidone
appeared to rescue BDNF expression back to near base-
line levels.
182,184
Studies have demonstrated that chronic or high doses of
typical antipsychotics, like haloperidol and reserpine, can
be neurotoxic, inducing apoptosis and reducing cell via-
bility. Though the mechanism remains unclear, high
doses of haloperidol induced apoptosis in the striatum
and substantia nigra of rats treated via acute intraperi-
toneal injection.
185 In vivo investigations have further
noted that brain regions like the striatum, hypothalamus,
and limbic structures were some of the most drastically
altered cytoarchitecturally by conventional antipsy-
chotics.
186 Macaque monkeys treated for 17 to 27 months
with therapeutic levels of either haloperidol or olanzap-
ine had reduced brain volumes by ~10%, most promi-
nently in the parietal and frontal brain lobes.
187 Other
studies found the opposite effect, that chronic treatment
of rats with haloperidol increased striatal volume.
188
In contrast, atypical antipsychotics appear to have some
neuroprotective functions. For example, pretreatment
with the atypical antipsychotics clozapine, quetiapine, or
risperidone prevented PC12 cell death following serum
withdrawal,
189 while olanzapine reduced cell death in
PC12, SH-SY5Y, and 3T3 cells following a number of
death-inducing treatments.
174 Neuroprotective proper-
ties have also been demonstrated for the atypical
antipsychotic olanzapine against various insults, such as
oxidative stressors
190 and ischemia.
191 Olanzapine also
upregulated the expression of Bcl-2 in rat frontal cortex
and the hippocampus, as well as the expression of BDNF
in the hippocampus.
176,181 Studies have suggested that
other atypical antipsychotics, such as risperidone and
quetiapine, have neuroprotective properties that might
be relevant to their clinical efficacy.
192,193 For instance, one
study found that the effects of stress-induced decreases
of BDNF could be prevented by pretreatment with que-
tiapine.
194
Overall, the findings suggest that antipsychotics can alter
prominent intracellular cascades and ultimately induce
neurotrophic or neurotoxic responses in vivo and in
vitro, depending upon the drug conditions, time course,
and brain region under consideration. 
Effects of antipsychotics on neurogenesis in animals 
Initial studies detected increased neurogenesis in the
gerbil hippocampus following haloperidol treatment,
195
but not in the rat hippocampus.
145Two more recent stud-
ies found that haloperidol did not affect neurogene-
sis,
196,197 although a study that used osmotic pumps
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drinking water) found that haloperidol increased neural
stem cell (NSC) proliferation in the adult rat forebrain.
198
Furthermore, the researchers demonstrated that this
proliferation was mediated through D2 receptor stimu-
lation in vitro, suggesting that under certain conditions,
haloperidol could promote neurogenesis through its sup-
pression of D2-mediated pathways that normally prevent
NSC proliferation. 
Atypical antipsychotics have shown a more consistent
profile of enhancing neurogenesis, but do not necessar-
ily increase neuronal survival or differentiation into
adult neurons. Chronic treatment of rats with clozapine
or olanzapine, for example, augmented the number of
BrdU-labeled cells in the dentate gyrus
196 or prefrontal
cortex and dorsal striatum.
197 Although both studies
detected increased proliferation of precursor cells, nei-
ther found a significant difference in the number of
BrdU-positive, mature neurons in the weeks following
treatment with antipsychotics. Quetiapine has also been
shown to reverse the inhibition of hippocampal neuro-
genesis caused by chronic restraint stress, and signifi-
cantly increase the number of BrdU-labeled immature
neurons detected compared with vehicle-treated,
stressed rats.
199
Effect of antipsychotics on NAA levels, brain volume,
and density in patients
Studies conducted with schizophrenic patients have
examined NAA measures and volumetric brain changes
using 1H-MRS and MRI, respectively, to elucidate the
effects of chronic antipsychotic treatment. Patients
treated with atypical antipsychotics had higher NAA
measures in the frontal lobes
200 and anterior cingulate
gyrus
201 than those treated with typical antipsychotics.
Another study measured NAA changes during antipsy-
chotic treatment and after cessation for at least 2 weeks
in individual patients using a within-subject design and
found significant decreases (~9%) in NAA levels in the
dorsolateral prefrontal cortex after ending antipsychotic
treatment; no differences were found in other brain
regions.
202
Schizophrenia, the disorder most often treated with
antipsychotics, is well-known to be associated with
reduced regional volumes, increased ventricle size,
203 and
deteriorating course,
204 making it difficult to distinguish
volumetric changes induced by antipsychotic treatment.
Overall, studies suggest that there are differences in the
brain volumes of patients treated with antipsychotics
compared with controls, or within groups of patients
treated chronically with typical versus atypical antipsy-
chotics; for a thorough analysis, see ref 186. One study
of patients with first-episode psychosis found that treat-
ment with haloperidol reduced grey matter volume; in
contrast, olanzapine-treated patients showed no signif-
icant reductions compared with controls.
205 Another
recent study found that olanzapine increased NAA in
the prefrontal cortex of remitted adolescent patients
with mania compared with nonremitted patients.
206
Although this suggests a possible in vivo neurotrophic
effect, this finding needs further replication because the
primary aim of the study—a NAA increase following
olanzapine treatment, independent from clinical
change—was negative. In fact, it is possible that the
NAA increase seen in responders was more closely
related to improved mood than to olanzapine’s neu-
rotrophic properties. 
Closing remarks
The growing data from molecular, cellular, animal, and
human studies described in this review support the
notion that psychotropic agents used to treat the major
psychiatric disorders—especially mood stabilizers—are
associated with significant neurotrophic/neuroprotective
effects. These effects may enhance cellular resilience and
plasticity in dysfunctional synapses and neural circuitry
implicated in psychiatric disorders. The crux of such
research is that, in addition to their proven ability to
treat psychiatric disorders, these agents may be useful in
the treatment of neurodegenerative illnesses and
ischemia. Similarly, psychotropic agents developed for
the treatment of neurodegenerative illnesses may be
beneficial as therapeutics for major psychiatric illnesses. 
Currently, several clinical trials are being conducted to
evaluate the feasibility of using lithium and valproate to
treat a variety of neurodegenerative diseases. Indeed,
neuroprotection is the most consistent biological out-
come associated with lithium treatment. There is hope
that these clinically safe and widely used agents will slow
disease progression, and perhaps produce functional
improvements. Furthermore, because lithium and val-
proate stimulate the ERK and PI3K pathways, increase
BDNF, Bcl-2, and BAG-1 expression, block HDAC
activity (valproate only), and inhibit GSK-3 alpha and
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cidate other clinically relevant targets, ultimately lead-
ing to improved treatments for these devastating disor-
ders. Additional data are also needed to understand
whether the neurotrophic and neuroprotective effects of
mood stabilizers, antidepressants, and antipsychotics are
cell-type or circuitry specific, and to what extent their
neurotrophic/neuroprotective effects contribute to their
therapeutic action. Finally, gaining insight into rapid-act-
ing versus long-term compensatory changes facilitated
by these psychotropic agents will pave the way for the
next generation of therapeutics, whose dual nature will
provide both a rapid treatment response to restore func-
tion, as well as support long-term changes to maintain
successful treatment and prevent relapse.  ❏
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Los efectos neurotróficos y neuroprotecto-
res de los agentes psicotrópicos
La evidencia acumulada sugiere que los agentes psi-
cotrópicos como los estabilizadores del ánimo, los
antidepresivos y los antipsicóticos producen sus
efectos neurotróficos/neuroprotectores mediante
la activación de la quinasa relacionada con la señal
de la proteinquinasa/extracelular activada por mitó-
geno, la quinasa PI3 y las vías de señales de la win-
gless/glicógeno sintetasa quinasa 3 (GSK). Estos
agentes también regulan hacia arriba la expresión
de moléculas tróficas/protectoras como el factor
neurotrófico cerebral, el factor de crecimiento neu-
ral, la proteína 2 del linfoma de células B, la quinasa
serina-treonina y el atanogen 1 asociado a Bcl-2, e
inactivan moléculas proapoptóticas como la GSK-3.
Ellos también promueven la neurogénesis y son
protectores en modelos de enfermedades neuro-
degenerativas e isquemia. La mayor parte, sino
toda esta evidencia se recolectó a partir de estudios
animales que utilizaron esquemas terapéuticos clí-
nicamente relevantes. Además, en humanos los
estudios de imágenes han encontrado que estos
fármacos aumentan el volumen y la densidad del
tejido cerebral, como también los niveles de N-ace-
til aspartato y glutamato en determinadas regiones
cerebrales. Tomados en conjunto, estos datos sugie-
ren que los efectos neurotróficos/neuroprotectores
de estos fármacos tienen un gran potencial tera-
péutico en el tratamiento no sólo de los trastornos
del ánimo y de la esquizofrenia, sino que también
en enfermedades neurodegenerativas y en la isque-
mia. 
Effets neuroprotecteurs et neurotrophiques
des psychotropes
D’après un nombre croissant d’arguments, les psy-
chotropes, comme les régulateurs de l’humeur, les
antidépresseurs et les antipsychotiques, exercent
leurs effets neurotrophiques et neuroprotecteurs
en activant 3 voies de signalisation : la MAP (mito-
gen activated protein)/ERK (extracellular signal-rela-
ted) kinase, la kinase PI3 et la Wnt/GSK (win-
gless/kinase glycogène synthase). Ces voies régulent
également positivement l’expression des molécules
trophiques/protectrices comme le BDNF (brain-deri-
ved neurotrophic factor), le NGF  (nerve growth fac-
tor), la protéine BCL2 (B-cell lymphoma 2), la kinase
sérine-thréonine et le BAG-1 (athanogène 1 associé
à BCL-2), et des molécules proapoptotiques inacti-
vées comme la GSK-3. Elles favorisent aussi la neu-
rogenèse et exercent un effet protecteur dans les
maladies neurodégénératives et l’ischémie. La plu-
part de ces preuves, si ce n’est toutes,  sont issues
d’études animales utilisant des schémas thérapeu-
tiques cliniquement pertinents. De plus, des études
d’imagerie sur l’homme ont montré que ces agents
augmentaient le volume et la densité du tissu céré-
bral ainsi que les taux de N-acétyl aspartate et de
glutamate dans les régions cérébrales sélectionnées.
Au total, ces données suggèrent que leurs effets
neurotrophiques/neuroprotecteurs ont un poten-
tiel thérapeutique large non seulement dans les
troubles de l’humeur et la schizophrénie mais aussi
dans les maladies neurodégénératives et l’ischémie.
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